Bioventus/$BVS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Bioventus
Bioventus Inc is a medical technology company. The company is engaged in developing and commercializing clinically differentiated treatments that engage and enhance the body's natural healing process. It offers a diverse portfolio of products to serve physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine and neurosurgery. Its portfolio of products is grouped into three verticals based on clinical use: Pain Treatments, Surgical Solutions, and Restorative Therapies. Geographical presence is in the United States which derives key revenue, and International markets.
Ticker
$BVS
Sector
Primary listing
Industry
Health Care Equipment & Supplies
Headquarters
Employees
930
ISIN
US09075A1088
Website
Bioventus Metrics
BasicAdvanced
$442M
-
-$0.48
0.85
-
Price and volume
Market cap
$442M
Beta
0.85
52-week high
$13.48
52-week low
$5.47
Average daily volume
367K
Financial strength
Current ratio
1.427
Quick ratio
0.806
Long term debt to equity
174.914
Total debt to equity
197.395
Interest coverage (TTM)
1.10%
Profitability
EBITDA (TTM)
58.809
Gross margin (TTM)
67.45%
Net profit margin (TTM)
-5.51%
Operating margin (TTM)
6.97%
Effective tax rate (TTM)
13.37%
Revenue per employee (TTM)
$610,000
Management effectiveness
Return on assets (TTM)
3.33%
Return on equity (TTM)
-20.24%
Valuation
Price to revenue (TTM)
0.765
Price to book
2.98
Price to tangible book (TTM)
-1.73
Price to free cash flow (TTM)
18.703
Free cash flow yield (TTM)
5.35%
Free cash flow per share (TTM)
35.61%
Growth
Revenue change (TTM)
8.60%
Earnings per share change (TTM)
37.52%
3-year revenue growth (CAGR)
6.77%
3-year earnings per share growth (CAGR)
12.64%
What the Analysts think about Bioventus
Analyst ratings (Buy, Hold, Sell) for Bioventus stock.
Bulls say / Bears say
Bioventus reported a 13.5% year-over-year increase in Q4 2024 revenue, reaching $153.6 million, driven by double-digit growth in Pain Treatments and Surgical Solutions. (benzinga.com)
The company reduced its net loss from continuing operations to $0.3 million in Q4 2024, a significant improvement from the $7.7 million loss in the prior year. (benzinga.com)
Bioventus secured a nationwide contract with Aetna™ Medicare Advantage plans, granting over 3 million members access to DUROLANE® for knee osteoarthritis treatment starting January 1, 2024. (globenewswire.com)
Bioventus shares have lost about 33.1% since the beginning of the year, underperforming the S&P 500's decline of -3.9%. (nasdaq.com)
The company reported a net loss attributable to Bioventus Inc. of $2.6 million in Q1 2025, compared to a net loss of $4.9 million in the prior-year period. (globenewswire.com)
Bioventus' Restorative Therapies segment experienced a marginal decline of 0.6% in Q4 2024, indicating potential challenges in that product line. (benzinga.com)
Data summarised monthly by Lightyear AI. Last updated on 5 Jun 2025.
Bioventus Financial Performance
Revenues and expenses
Bioventus Earnings Performance
Company profitability
Bioventus News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Bioventus stock?
Bioventus (BVS) has a market cap of $442M as of June 28, 2025.
What is the P/E ratio for Bioventus stock?
The price to earnings (P/E) ratio for Bioventus (BVS) stock is 0 as of June 28, 2025.
Does Bioventus stock pay dividends?
No, Bioventus (BVS) stock does not pay dividends to its shareholders as of June 28, 2025.
When is the next Bioventus dividend payment date?
Bioventus (BVS) stock does not pay dividends to its shareholders.
What is the beta indicator for Bioventus?
Bioventus (BVS) has a beta rating of 0.85. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.